CTX Insider Trading

Insider Ownership Percentage: 10.71%
Insider Buying (Last 12 Months): C$14,405.00
Insider Selling (Last 12 Months): C$0.00

Crescita Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Crescita Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Crescita Therapeutics Share Price & Price History

Current Price: C$0.44
Price Change: Price Increase of +0.015 (3.57%)
As of 06/21/2024 10:01 PM ET

This chart shows the closing price history over time for CTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Crescita Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/22/2023Jose DarochaDirectorBuy33,500C$0.43C$14,405.00
8/16/2022Anthony Edward DobranowskiDirectorBuy15,638C$0.69C$10,749.56100,000
See Full Table

SEC Filings (Institutional Ownership Changes) for Crescita Therapeutics (TSE:CTX)

Crescita Therapeutics logo
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers (MMPE) and DuraPeel for the development of topicals containing cannabis and hemp. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription portfolio offers dermocosmetic products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud brand; and provides medical aesthetics under Pro-Derm and Alyria brands, for non-invasive and minimally invasive procedures or skincare treatments. In addition, it distributes NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; and ART FILLER, hyaluronic acid-based dermal fillers. The company has a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.
Read More on Crescita Therapeutics

Today's Range

Now: C$0.44
Low: C$0.44
High: C$0.44

50 Day Range

MA: C$0.43
Low: C$0.42
High: C$0.48

52 Week Range

Now: C$0.44
Low: C$0.36
High: C$0.73

Volume

3,500 shs

Average Volume

16,964 shs

Market Capitalization

C$8.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.65

Who are the company insiders with the largest holdings of Crescita Therapeutics?

Crescita Therapeutics' top insider shareholders include:
  1. Anthony Edward Dobranowski (Director)
  2. Jose Darocha (Director)
Learn More about top insider investors at Crescita Therapeutics.